^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Epkinly (epcoritamab-bysp) (CD20 inhibitor, CD3 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Excerpt:
...Documented CD20 positive mature B cell neoplasm or CD20+ MCL...
Trial ID:
Source:
Title:
1655 Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort
Published date:
11/02/2023
Excerpt:
Pts with CD20+ R/R FL (grade [G] 1–3A) who had received ≥2 prior lines of systemic tx received epcoritamab...The ORR was 82%, with a complete response (CR) rate of 63% (Figure). The median time to response and CR was 1.4 and 1.5 mo, respectively. ORRs/CR rates were generally consistent across prespecified high-risk subgroups: double refractory, 76%/56%; refractory to last prior tx, 74%/51%; POD24, 80%/61%...Single-agent epcoritamab SC resulted in deep and durable responses with high ORR and CR rates in hard-to-treat, high-risk pts with R/R FL. Responses were consistent across subgroups.
Trial ID:
Source:
Title:
016 | SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI-TUMOR ACTIVITY
Published date:
06/09/2021
Excerpt:
Adults with R/R CD20+ B-NHL received flat-dose 1 mL SC epcoritamab (step-up dosing approach) in 28-day cycles…ORR for patients with FL at doses ≥12 mg (n = 5) was 80% (CR = 60%; PR = 20%); ORR for patients with MCL at doses ≥0.76 mg (n = 4) was 50% (CR = 25%; PR = 25%).
Source:
Title:
Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.
Published date:
05/19/2021
Excerpt:
Adults with R/R CD20+ B-NHL received flat-dose 1 mL SC epcoritamab (step-up dosing approach) in 28-day cycles....68 pts with B-NHL were enrolled across histologies including diffuse large B-cell lymphoma (DLBCL; n = 46 [67.6%]; de novo and transformed), follicular lymphoma (FL; 12 [17.6%])....Overall response is shown for DLBCL ≥12 mg and ≥48 mg and FL ≥12 mg, corresponding to the minimal efficacy threshold (Table). Responses deepened over time (PR converted to CR: DLBCL, 6 pts; FL, 3 pts)...SC epcoritamab demonstrated substantial single-agent activity, inducing deep and durable clinically meaningful responses, with a consistent safety profile.
DOI:
10.1200/JCO.2021.39.15_suppl.7518
Trial ID:
Source:
Title:
Subcutaneous (SC) Epcoritamab (GEN3013; DuoBody-CD3×CD20) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Dose-Escalation Data from a Phase I/II Trial
Published date:
09/14/2020
Excerpt:
Adults with R/R CD20+ B-NHL….58 patients with a median (range) age 68 (21–84) years were enrolled. Most patients had DLBCL (67.2%) or FL (19.0%) and received a median (range) of 3 (1–6) and 5 (1–18) prior lines of treatment, respectively….Antitumor activity (14 May 2020) in evaluable patients with DLBCL...DLBCL (n=15): ORR 60.0% (CR: 20.0%; PR: 40.0%), SD: 6.7%, PD: 33.3%. FL (n=7): ORR 85.7% (PR: 85.7%), SD: 14.3%,...
Trial ID:
